The MAA for VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in adults has been submitted to the MHRA – LENZ Therapeutics
LENZ Therapeutics announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval… read more.
